Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
The theoretical basis of 'total androgen blockade' in the treatment of advanced prostatic cancer is reviewed. The results of experimental and clinical data in the literature comparing medical or surgical castration alone versus castration plus peripheral antiandrogens are discussed. Most of these studies could not reproduce Labrie's results and do not establish the benefit of total androgen blockade. The author produces his own experience with LHRH analogs alone (Depot Zoladex; 30 patients) compared to orchidectomy plus antiandrogens (17 patients). After 2 years, there is no difference in the progression and death rates between the two groups. Moreover, the administration of an antiandrogen in 15 patients relapsing after first-line hormonal treatment (Zoladex or orchidectomy) produced an objective response in only 2 of them. 9 patients experienced a subjective response but the duration of response was very short (medium 3 months).
Bouffioux
C
C
Urological Department, University Hospital, Liège, Belgium.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005485:Flutamide / Q000627:therapeutic use; D017273:Goserelin; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D013997:Time Factors
D000726:Androgen Antagonists; D017273:Goserelin; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D002064:Buserelin